z-logo
Premium
Gastrointestinal safety across the albiglutide development programme
Author(s) -
Leiter L. A.,
Mallory J. M.,
Wilson T. H.,
Reinhardt R. R.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12679
Subject(s) - liraglutide , placebo , tolerability , medicine , nausea , vomiting , gastroenterology , adverse effect , type 2 diabetes , endocrinology , diabetes mellitus , alternative medicine , pathology
Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment‐related AEs associated with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in the treatment of type 2 diabetes mellitus. The GI safety of albiglutide, a once‐weekly GLP‐1RA, was assessed using data from five phase III studies. In a pooled analysis of four placebo‐controlled trials, the most common GI AEs were diarrhoea (albiglutide, 14.5% vs. placebo, 11.5%) and nausea (albiglutide, 11.9% vs. placebo, 10.3%), with most patients experiencing 1–2 events. The majority were mild or moderate in intensity and their median duration was 3–4 days. Vomiting occurred in 4.9% of patients in the albiglutide vs. 2.6% in the placebo group. For both albiglutide and placebo, serious GI AEs (2.0% vs. 1.5%) and withdrawals attributable to GI AEs (1.7% vs. 1.5%) were low. In a 32‐week trial of albiglutide 50 mg weekly versus liraglutide 1.8 mg daily, nausea occurred in 9.9% of patients in the albiglutide group vs. 29.2% in the liraglutide group. Vomiting occurred in 5.0% in the albiglutide vs. 9.3% in the liraglutide group. In conclusion, albiglutide has an acceptable GI tolerability profile, with nausea and vomiting rates slightly higher than those for placebo but lower than those for liraglutide.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here